SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Inclusion Criteria: * 1.Participantss aged 18-75 years (inclusive); * 2\. Pathologically confirmed patients with locally advanced or metastatic urothelial carcinoma * 3 Participants havefailed of platinum-based chemotherapy and PD-(L)1 inhibitors; for participants who received platinum-based chemotherapy and PD-(L)1 inhibitors in the adjuvant/neoadjuvant setting, disease recurrence or progression must have occurred within 12 months after completion of that therapy; radiographically confirmed disease progression during or after the most recent treatment regimen; * 4 Participants must have measurable disease according to RECIST (version 1.1); * 5 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * 6 Life expectancy of ≥ 3 months; * 7 Adequate major organ function (hematology, renal, liver, and coagulation) as determined by laboratory tests performed within 7 days prior to treatment; * 8 Sexually active fertile participants must agree to use methods of contraception during the study and at least 6 months after termination of study therapy and have a negative urine or serum pregnancy test within 7 days prior to randomization; * 9 Willing to participate in the study, understand the study procedures, and sign a written informed consent form. Exclusion Criteria: * 1\. Active central nervous system metastases or leptomeningeal metastasis; * 2\. Prior Nectin-4-targeted therapy; * 3\. Adverse events from prior antitumor therapy not recovered to Grade ≤ 1 per NCI-CTCAE v5.0； * 4\. Any serious and/or uncontrolled concurrent illness that may interfere with patient's participation in the study: 1. History of severe cardiovascular disease within 6 months prior to randomization, including but not limited to: 1. Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia and third-degree atrioventricular block requiring clinical intervention; corrected QT interval \> 480 ms by Fridericia method (Fridericia formula: QTcF = QT/RR\^0.33, RR = 60/heart rate); 2. With history of myocardial infarction, unstable angina pectoris, angioplasty and coronary artery bypass surgery; 3. New York Heart Association (NYHA) classification Grade III and above heart failure, and left ventricular ejection fraction (LVEF) \< 50% in the tests and examinations during the screening period; 4. Ischemic or Hemorrhagic Stroke; 5. Pulmonary Embolism Accident; 2. Other clinically significant diseases: 1. HbA1c \> 8%; 2. Participants with active keratitis and corneal ulcer, or fundus lesions with a risk of blindness; 3. Grade ≥2 neuropathy prior to randomization; 4. Severe infection within 4 weeks prior to randomization; Active infection of Grade ≥2 (CTCAE v5.0) requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to randomization; 5. Active HBV or HCV infection; 6. History of immunodeficiency (HIV-positive, acquired or congenital immunodeficiency, etc.), or organ transplantation; 7. History of another malignancy within 3 years prior to randomization; 8. History of interstitial lung disease (ILD) / non-infectious pneumonia, or current ILD/non-infectious pneumonia, or imaging findings at screening that cannot rule out these condition, except for those who are determined to be risk-free after discussion between the investigator and the sponsor; 9. Pleural effusion, ascites or pericardial effusion with syptoms or requiring puncture or drainage within 2 weeks prior to randomization; * 5\. Use of other unmarketed clinical investigational drugs or treatments, chemotherapy, radiotherapy, or targeted therapy within 4 weeks prior to randomization; use of traditional Chinese medicine with anticancer indication, oral fluoropyrimidine drugs, small molecule targeted drug within 2 weeks prior to randomization; use of palliative radiation or local therapy within 2 weeks prior to randomization; or major surgery within 4 weeks prior to randomization; * 6\. Allergy to any component of SYS6002 or to humanized monoclonal antibodies; * 7\. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.